Key result
OSA linked to ~70% higher MACCE risk in female ACS patients with metabolic syndrome.
Why the study?
Whether comorbid obstructive sleep apnea increases cardiovascular consequences in acute coronary syndrome patients with metabolic syndrome had not been investigated.
Does comorbid obstructive sleep apnea increase the risk of major adverse cardiovascular and cerebrovascular events in patients with acute coronary syndrome and metabolic syndrome?
Cohort (n=1,927)
Does comorbid obstructive sleep apnea increase the risk of major adverse cardiovascular and cerebrovascular events in patients with acute coronary syndrome and metabolic syndrome?
Effect estimate: adjusted HR 1.29 (95% CI 0.99-1.67)
Absolute Event Rate: 21.9% vs 17.9%
p-value: p=.06
Comorbid obstructive sleep apnea is associated with an increased risk of major adverse cardiovascular and cerebrovascular events specifically in female patients with acute coronary syndrome and metabolic syndrome.
BACKGROUND: Obstructive sleep apnea (OSA) and metabolic syndrome (MetS) are each increasingly common in patients with acute coronary syndrome (ACS). Whether OSA increases cardiovascular consequences in ACS patients with MetS has not been investigated. HYPOTHESIS: OSA increases cardiovascular risk in ACS patients with MetS. We aimed to examine the association between OSA and cardiovascular consequences in ACS patients with MetS. METHODS: In this prospective cohort study, we consecutive recruited 2160 ACS patients who underwent portable sleep breathing monitoring. OSA is defined as an apnea-hypopnea index (AHI) ≥ 15 events/h. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), including cardiovascular death, myocardial infarction, stroke, ischemia-driven revascularization, or hospitalization for unstable angina or heart failure. RESULTS: A total of 1927 patients with ACS were enrolled. Among them, 1486 (77.1%) had MetS and 1014 (52.6%) had OSA. During 2.9 years of follow-up, the cumulative incidence of MACCE was similar between OSA and non-OSA groups in patients with MetS (21.9% vs. 17.9%, adjusted hazard ratio [HR] = 1.29 95% confidence interval [CI]: 0.99-1.67, p = .06) and patients without MetS (24.4% vs. 17.3%, adjusted HR = 1.21 95% CI: 0.73-2.03, p = .46). Patients with MetS and OSA had a significantly higher risk of MACCE than patients with MetS and without OSA in women (27.8% vs. 18.1%, adjusted HR = 1.70, 95% CI: 1.01-3.09, p = .04) but not in men (21.0% vs. 17.9%, adjusted HR = 1.19, 95% CI: 0.91-1.59, p = .21). CONCLUSIONS: In hospitalized ACS patients with MetS, comorbid OSA was associated with increased risk of cardiovascular consequences among women.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted a cohort in Acute coronary syndrome with metabolic syndrome (n=1,927). Obstructive sleep apnea (OSA) vs. Non-OSA was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE), including cardiovascular death, myocardial infarction, stroke, ischemia-driven revascularization, or hospitalization for unstable angina or heart failure (adjusted HR 1.29, 95% CI 0.99-1.67, p=.06). Comorbid obstructive sleep apnea in female ACS patients with metabolic syndrome was associated with a higher risk of MACCE compared to those without OSA (27.8% vs. 18.1%; adjusted HR 1.70; p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: